Taiwan, No Longer a Life-Sciences Island Unto Itself - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Taiwan, No Longer a Life-Sciences Island Unto Itself
Taking a cue from its electronics industry, Taiwan is seeking to put its biotechnology and pharmaceutical industries on the map. An interactive map shows pharmaceutical activity in Taiwan.


Pharmaceutical Technology
Volume 33, Issue 5

Pharmaceutical outsourcing

In a recent PricewaterhouseCoopers (PwC) analysis, Taiwan ranked fourth as a destination for pharmaceutical outsourcing in Asia, trailing only China and India, which respectively ranked number one and two, and Korea, which was rated third (1, 2). The ranking was based on a weighted index that factored in costs (compensation, infrastructure, tax, and regulatory), risks (geopolitical, human capital, economic risks, legal, and infrastructure), and market opportunity (current and future needs of the aging population, pharmaceutical market size and growth).

Taiwan's positive ranking is a result of government policy to develop its biotechnology industry, drug-development activities, and broaden the use of contract research organizations (CROs). In 2000, the country replaced local registration requirements for clinical trials with bridging evaluations that followed international standards, according to the PwC report (1). This action provided the framework for multinational companies to consider Taiwan in its clinical research activities, but also provided opportunity for domestic CROs. The government also introduced tax incentives to encourage Taiwanese pharmaceutical companies to employ CROs. CROs were also given the right to represent sponsor companies in applying for investigational new drug applications under a new drug approval system, which was introduced in 2007, as a means to make the drug-approval process more transparent and efficient (1).

These efforts have made some inroads. Taiwan is competitive with other Asian countries in its clinical-trials activities based on a review of open clinical trials from ClinicalTrials.gov/, a registry of federally and privately supported clinical trials in the United States and globally. Taiwan had 772 open clinical trials as of Apr. 13, 2009, compared with 607 in Korea, 573 in China, and 398 in India, according to ClinicalTrials.gov/ (3). Big Pharma, however, is a lead sponsor in only a handful of these trials. A review of the top 20 pharmaceutical companies shows Pfizer with the greatest number of open clinical trials (26 trials) conducted in Taiwan in which a Big Pharma company is a lead sponsor. GlaxoSmithKline and Bristol-Myers Squibb have the next highest totals, each with 18, followed by Roche (Basel, Switzerland) with 14, and Boehringer-Ingelheim with 12 (3, 4).

Multinational and domestic CROs are building their presence in Taiwan. In 2007, Parexel International (Boston) acquired the Taiwanese CRO Apex International Clinical Research for NT$1.7 billion ($50.9 million). Parexel, with annual sales of approximately $1.3 billion, is one of the largest global CROs, and Apex was one of Taiwan's largest CROs at the time of the acquisition. The Japanese CRO EPS (Tokyo) opened a branch in Taiwan in 2007 and the CRO CMIC (Tokyo) also has operations in Taiwan.


Table I: Select contract research and manufacturing organizations in Taiwan.
The number of suppliers of pharmaceutical raw materials and intermediates and contract manufacturing organizations (CMOs) in Taiwan is still small compared with the number in China and India, which are more established in the pharmaceutical supply chain. One measure of this difference is the number of exhibitors from these respective countries at CPhI Worldwide, the large international trade show of pharmaceutical ingredient suppliers, which includes pharmaceutical and chemical suppliers and manufacturers. At the 2008 show, which was held in Frankfurt, approximately 430 exhibitors were from China, 200 from India, and only 13 from Taiwan. Table 1 lists select CMOs from Taiwan.

ScinoPharm Taiwan (Shan-Hua, Tainan Country) is a leading Taiwanese CMO providing process R&D, custom synthesis of early-phase materials, and manufacturing of generic APIs. It was founded in 1997 by two former executives at Syntex, a pharmaceutical company acquired by Roche in 1994. Jo Shen, president and CEO of ScinoPharm, was formerly corporate vice-president for pharmaceutical technology and operations at Syntex. Hardy W. Chan, executive vice-president of ScinoPharm Taiwan, was formerly Syntex's vice-president of research and director of biotechnology.

The Taiwanese government holds a 16% stake in ScinoPharm, and the US generic-drug manufacturer Watson Pharmaceuticals (Corona, CA) hold 31%. Watson invested nearly $47 million between 2004 and 2006 to increase its equity position in Scinopharm, according to Watson's 2007 annual filing. In addition to its primary API manufacturing facility (which operates under good manufacturing practices [GMP]) in Tainan City, ScinoPharm operates facilities in China. These facilities include process R&D laboratories and a kilo-scale laboratory in Kunshan, Jiangsu Province, and a manufacturing facility in Taicang, Jiangus Province. Its Chinese operations provide process R&D of API intermediates, scale-up, and nonGMP manufacturing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here